These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 31235408

  • 1. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Lim TS, Rhee H, Kim GM, Kim SU, Kim BK, Park JY, Ahn SH, Han KH, Choi JY, Kim DY.
    J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S, Rhim H, Kim YS, Kang TW, Song KD.
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [Abstract] [Full Text] [Related]

  • 8. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
    Zhang YQ, Jiang LJ, Wen J, Liu DM, Huang GH, Wang Y, Fan WZ, Li JP.
    J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
    [Abstract] [Full Text] [Related]

  • 9. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
    Lee MH, Kim SU, Kim DY, Ahn SH, Choi EH, Lee KH, Lee DY, Seong J, Han KH, Chon CY, Park JY.
    J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
    [Abstract] [Full Text] [Related]

  • 10. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
    Zhao SM, Qiu LW, Zhao H, Gu WW, Yang XH, Gu ZX, Shi RF, Ni CF.
    J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
    [Abstract] [Full Text] [Related]

  • 11. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Park WH, Shim JH, Han SB, Won HJ, Shin YM, Kim KM, Lim YS, Lee HC.
    J Vasc Interv Radiol; 2012 Jul; 23(7):927-36. PubMed ID: 22633621
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
    Chon YE, Choi GH, Lee MH, Kim SU, Kim DY, Ahn SH, Kim KS, Choi JS, Han KH, Chon CY, Park JY.
    Int J Cancer; 2012 Nov 15; 131(10):2332-41. PubMed ID: 22362471
    [Abstract] [Full Text] [Related]

  • 16. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N.
    Ann Surg Oncol; 2009 Oct 15; 16(10):2795-804. PubMed ID: 19669841
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
    Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Yoshimatsu R, Yamagami T, Awai K, Chayama K.
    J Gastroenterol Hepatol; 2015 Apr 15; 30(4):726-32. PubMed ID: 25311578
    [Abstract] [Full Text] [Related]

  • 18. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K, Shigematsu H, Irie K, Ishibashi H.
    Hepatogastroenterology; 2003 Apr 15; 50(54):2072-8. PubMed ID: 14696467
    [Abstract] [Full Text] [Related]

  • 19. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, Takasaki K, Nakano M.
    J Gastroenterol Hepatol; 2002 Jul 15; 17(7):772-8. PubMed ID: 12121507
    [Abstract] [Full Text] [Related]

  • 20. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
    Song P, Feng X, Inagaki Y, Song T, Zhang K, Wang Z, Zheng S, Ma K, Li Q, Kong D, Wu Q, Zhang T, Zhao X, Hasegawa K, Sugawara Y, Kokudo N, Tang W, Japan-China Joint Team for Medical Research and Cooperation on HCC.
    Biosci Trends; 2014 Oct 15; 8(5):266-73. PubMed ID: 25382443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.